Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Fintech pioneer Tom Sosnoff discusses the evolution of retail investing, the rise of AI, and his new platform Lossdog aimed at the next generation of trading.
The FAA prepares to select cities for its eVTOL pilot program, marking a major step toward electric air taxis and the future of urban air mobility in the U.S.
Rising oil prices tied to the Iran conflict are driving up gas and airfare costs, creating new challenges for travelers heading into the spring break season.
The Supreme Court strikes down Trump-era tariffs, limiting presidential trade powers and raising questions about refunds, global trade, and business impact.
New research from GoDaddy and UCLA shows small businesses signal shifts in GDP, jobs, and digital growth earlier than traditional data or Wall Street trends.
GoFundMe launches Back in Business Fund with Paris Hilton to provide targeted grants helping women entrepreneurs recover and rebuild after natural disasters.
